Skip to content

A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg / 5 mL of clavulanic acid powder for oral suspension in healthy volunteers under fed conditions.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-522562-70-00
Enrollment
56
Registered
2025-08-26
Start date
2025-09-08
Completion date
2025-12-17
Last updated
2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infection

Interventions

None listed

Sponsors

Tarchominskie Zaklady Farmaceutyczne Polfa S.A.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Czechia

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026